It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Some vaccines may reduce the risk of dementia through a double effect in which the jabs help protect the brain through their ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

A new study shows that a vaccine against respiratory syncytial virus is associated with a 29% reduction in dementia risk in ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

New research suggests vaccines against "potentially serious and life-threatening infections" could offer double protection ...